CF drug maker offers treatment at surcharge of €23,000 per patient
Cystic Fibrosis Ireland boss says ‘no justification for price differential’ with Britain
The manufacturer of the breakthrough Cystic Fibrosis drug called Orkambi proposed charging €23,000 more per person for its drug in Ireland compared with England.
Vertex offered a €158,000 price tag per patient per year to the Irish health service in the submission it made a few months ago.
Vertex then offered England’s National Health Service (NHS) a list price of €135,000 (£104,000) per patient per year.
Philip Watt, chief executive of Cystic Fibrosis ...
